STAT

MARCH 10, 2023

Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now, as federal regulators step in to clean up SVB’s mess, biotech startups are left wondering: What happens to their money, and who’s going to finance the industry? On Friday morning, the Federal Deposit Insurance Corporation took control of SVB and is presiding over a sale of the firm’s assets to cover clients’ deposits.

363

363

PharmaVoice

MARCH 8, 2023

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

246

246

ALiEM - Pharm Pearls

MARCH 6, 2023

A 48-year-old female with a past medical history of opioid use disorder on suboxone presents with abdominal pain for one day. The patient developed sharp diffuse upper abdominal pain the evening prior to arrival that resolved. The pain recurred again today and was associated with bilious emesis. The patient notes persistent upper abdominal pain with paroxysmal exacerbation.

Hospitals 189

Hospitals 189

LifeProNow

MARCH 10, 2023

March 09, 2023: “The U.S. Food and Drug Administration announced it is requesting $7.2 billion as part of the president’s fiscal year (FY) 2024 budget. This funding will allow the agency to continue to leverage new and emerging technologies, recruit and support a highly skilled workforce and adapt oversight to new production and business models.

Labelling 130

Labelling Packaging Controlled Substances 130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

MARCH 9, 2023

WASHINGTON — Pfizer CEO Albert Bourla made the maximum possible campaign contribution to Mehmet Oz ahead of his failed bid last year to represent Pennsylvania in the U.S. Senate, according to federal campaign finance records. Oz is well-known for spreading medical misinformation , including touting astrology as a legitimate medical tool and the myth that apple juice contains unsafe levels of arsenic — a surprising political ally for Bourla, who runs one of the largest pharmaceutica

Pharmaceutical Companies 349

Pharmaceutical Companies Pharmaceutical Companies 349

PharmaVoice

MARCH 9, 2023

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

246

246

European Pharmaceutical Review

MARCH 9, 2023

A pilot study has demonstrated that a nasal version of the drug Foralumab, an anti-CD3 monoclonal antibody suppressed the inflammatory T cell response and decreased lung inflammation in patients with COVID-19. “This is the first nasal monoclonal antibody—other monoclonal antibody treatments were delivered intravenously and are no longer given as treatment because they are not effective against currently circulating viral variants,” explained Dr Howard Weiner, founder and Director of the Brigham

Immunity 145

Immunity Immunization Medical Schools Hospitals 145

STAT

MARCH 9, 2023

This is part of a series about new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity Revolution. “Anne” is sitting in a small, wood-paneled consultation room, at the Mayo Clinic in Rochester, Minn., about to embark on yet another weight loss journey.

Mayo Clinic 298

Mayo Clinic 298

PharmaVoice

MARCH 8, 2023

How a 32-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.

246

246

Pharmaceutical Technology

MARCH 10, 2023

On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. A £9.3 million ($11 million) grant is being used to build the facility in Bristol where therapies for currently incurable diseases, such as some forms of cancer, sickle cell disease, and cystic fibrosis can be manufactured.

Communication 105

Communication 105

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

European Pharmaceutical Review

MARCH 10, 2023

Today marks the opening the NHS Blood and Transplant (NHSBT)’s new Clinical Biotechnology Centre (CBC) in Bristol. The state-of-the-art facility was part-funded by a £9.43 million Government grant and is designed to expand the UK’s ability to manufacture new gene and cell therapies. The CBC will help the UK grow its cell and gene therapy industry in a rapidly growing international market.” “The CBC will help the UK grow its cell and gene therapy industry in a rapidly growing international

Vaccines 127

Vaccines 127

STAT

MARCH 10, 2023

For graduating medical students hoping to secure a residency training position — and that’s virtually all of them — Match Day is the most anticipated day of the year. The Match is the culmination of medical school, application preparation, interviews, and recruitment events. It’s like a traditional job search but without the room for negotiation since it is based on an algorithm that announces job placement once a year, on the third Friday of March, for all participat

Medical Schools 288

Medical Schools 288

PharmaVoice

MARCH 7, 2023

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

240

240

Pharmaceutical Technology

MARCH 8, 2023

Eli Lilly has announced that it will reduce the price of its most commonly used insulin, Humalog, in the US, by 70% and cap the out-of-pocket cost for those on commercial insurance at $35. This follows on from recent US federal action, the Inflation Reduction Act, that legislated reducing the Medicare beneficiary insulin out-of-pocket costs at $35 a month.

Biosimilars 105

Biosimilars Diabetes 105

Pharma Times

MARCH 9, 2023

FlyPharma Europe chose Vienna for its latest conference due to the growing presence of Austrian biotechnology and pharmaceutical manufacturing

Pharmaceutical Manufacturing 112

Pharmaceutical Manufacturing 112

STAT

MARCH 7, 2023

The diversity of medical school classes has barely budged in recent decades, even with the ability to consider an applicant’s race as one factor in admissions. Now, many medical school leaders fear a looming U.S. Supreme Court decision to restrict or ban race-conscious admissions policies could lead to precipitous declines, imperiling efforts to fight the nation’s stark racial and ethnic health disparities.

Medical Schools 259

Medical Schools 259

PharmaVoice

MARCH 10, 2023

IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

130

130

Pharmaceutical Technology

MARCH 6, 2023

Incannex Healthcare has collaborated with New Jersey-based pharma company Catalent for the development and manufacturing of a cGMP-grade psilocybin drug product for clinical trials and potential commercial use. The drug product is designed for use in the psilocybin-assisted psychotherapy drug development programme of Incannex for generalised anxiety disorder.

Drug Development 105

Drug Development 105

PharmExec

MARCH 8, 2023

According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.

105

105

STAT

MARCH 8, 2023

Teletherapy has made mental health care more accessible than ever before, making care possible for people who otherwise would never have been able to get it. But the antiquated system of licensure in the United States is creating a huge barrier to realizing the potential for telehealth. I’ve seen the benefits of teletherapy firsthand. As the founder and CEO of Alma, a mental health company that helps independent mental health providers run their private practice and accept insurance, we s

258

258

PharmaVoice

MARCH 6, 2023

As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

163

163

Pharma Times

MARCH 6, 2023

Vaccines developed at the facility will cover a wide range of respiratory diseases

Vaccines 140

Vaccines 140

PharmExec

MARCH 7, 2023

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.

Drug Pricing 126

Drug Pricing 126

STAT

MARCH 5, 2023

This is the first article in a series about new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity Revolution. A two-part message is permeating the halls of medicine and the fabric of society, sliding into medical school lectures, pediatricians’ offices, happy hours and social feeds: Obesity is a chronic biological disease — and it’s treatable with a new

Medical Schools 246

Medical Schools Drug Development Diabetes 246

PharmaVoice

MARCH 9, 2023

The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

130

130

Pharmaceutical Technology

MARCH 7, 2023

Clene has presented updated trial results for its Visionary MS Phase II clinical trial for its lead pipeline candidate, CNM-Au8. The trial is investigating CNM-Au8 as a treatment for patients with relapsing forms of multiple sclerosis (MS) with chronic optic neuropathy. The agent has a first-in-class mechanism of action within the MS portfolio, as it is a first drinkable treatment based on a nanocrystalline gold suspension that has reached late-stage development for MS.

100

100

Pharmaceutical Business Review

MARCH 6, 2023

Selagine is a spin-out company from the University of Illinois at Chicago (UIC), while Grifols is a provider of plasma-derived medicines. A biologic drug, an immunoglobulin eye drop features naturally occurring functional antibodies produced from human plasma gathered from thousands of healthy donors. These antibodies are capable of neutralising inflammatory proteins, such as Interferon-gamma, Interlukin-17 and matrix metalloproteinase-9 that are implicated in generating ocular surface disease i

98

98

STAT

MARCH 7, 2023

WASHINGTON — It’s hard to shop for health insurance. It’s harder still when there’s few options to help. Some Americans who can’t rely on a federal program or their employers’ HR department turn to brokers who are trained to help them navigate the complex web of deductibles, formularies, and subsidies. But in 2021 in Hartford, Bridgeport, and New Haven, Connecticut — as in many poorer areas in the U.S.

245

245

Pharmafile

MARCH 10, 2023

A new state-of-the-art facility named the Clinical Biotechnology Centre (CBC) is opening in Bristol, UK. It cost approximately £10m to build, funded by the UK Government. CBC is aiming to support the UK’s cell and gene therapy (CGT) industry, from manufacturing DNA plasmids and viral vectors which are used to create gene and genetically modified cell therapies, to supporting early phase clinical trials and preclinical work.

Communication 97

Communication 97

Pharmaceutical Technology

MARCH 10, 2023

The US Food and Drug Administration (FDA) has granted approval for Pfizer ’s Zavzpret (zavegepant) for the acute treatment of migraine in adult patients with or without aura. Zavzpret is claimed to be the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved to treat migraine. It is a third-generation, selective and structurally unique, small molecule CGRP receptor antagonist and is currently under clinical development with oral and intranasal formulation

98

98

Drug Patent Watch

MARCH 4, 2023

Annual Drug Patent Expirations for ORKAMBI Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. It is available from one supplier. There are twenty… The post New patent for Vertex Pharms drug ORKAMBI appeared first on DrugPatentWatch - Make Better Decisions.

97

97

STAT

MARCH 9, 2023

WASHINGTON — The Biden administration is calling for a big boost for public health funding across the federal health department, but left out specific funding for Covid-19 activities. In its budget request to Congress on Thursday, the White House asked for $20 billion over five years to support pandemic preparedness efforts at the Administration for Strategic Preparedness and Response, Centers for Disease Control and Prevention, National Institutes of Health, and the Food and Drug Adminis

244

244

PharmaState Academy

MARCH 9, 2023

Registrations Open Now Limited Seats Master the Art of "Brand Differentiation" and Grow Faster Than Competitors! 550+ Registrations Done! BOOK SEAT Invest in yourself! Masterclass on "The Art Of Brand Differentiation" Learn how to set your brand apart with a unique identity and win brand prescribers. 26th March 2023 (Sunday) 10:00 AM - 11:30 AM (IST) Days Hours Minutes Seconds Masterclass on "The Art Of Brand Differentiation" Learn how to set your brand apart with a unique identity and win brand

95

95

Pharmaceutical Technology

MARCH 8, 2023

The US Food and Drug Administration (FDA) has granted approval for Shorla Oncology’s Nelarabine Injection, an oncology drug, to treat T-cell leukaemia, an aggressive blood and bone marrow cancer that progresses quickly. The oncology drug has been approved to treat T-cell Lymphoblastic Lymphoma (T-LBL) and T-cell Acute Lymphoblastic Leukemia (T-ALL).

98

98

Drug Patent Watch

MARCH 4, 2023

Annual Drug Patent Expirations for SYMDEKO+%28COPACKAGED%29 Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are… The post New patent for Vertex Pharms drug SYMDEKO (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.

96

96